Comparative hemodynamics of antiarrhythmic drugs

It is important to consider the hemodynamic effects of antiarrhythmic drugs, because the majority of patients who require these drugs already have compromised cardiac function. The presently available antiarrhythmic agents vary in their potential for producing negative inotropic effects on the myoca...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 1990-06, Vol.4 Suppl 3 (S3), p.545-548
Main Author: Sami, M
Format: Article
Language:English
Subjects:
Administration, Oral
Anti-Arrhythmia Agents - administration & dosage
Anti-Arrhythmia Agents - pharmacology
Hemodynamics - drug effects
Humans
Injections, Intravenous
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c156t-2d455e5c9098d767e24200d0091b927dff65981b3fc6bdeea0bde1d3aaa1337e3
container_end_page 548
container_issue S3
container_start_page 545
container_title Cardiovascular drugs and therapy
container_volume 4 Suppl 3
creator Sami, M
description It is important to consider the hemodynamic effects of antiarrhythmic drugs, because the majority of patients who require these drugs already have compromised cardiac function. The presently available antiarrhythmic agents vary in their potential for producing negative inotropic effects on the myocardium; they vary, as well, as to the mechanisms by which these effects are produced. The drugs in each of the Vaughan-Williams' classes are discussed in terms of the extent to which they affect cardiac output and the mechanisms by which they may depress cardiac function. Practically all antiarrhythmic agents can decrease cardiac output when administered intravenously. However, when given orally to patients with congestive heart failure, amongst Class I agents, encainide and mexilitine appear to have a reasonably good safety record with respect to the worsening of congestive heart failure. Class III antiarrhythmics also appear to be well tolerated in patients with severe LV dysfunction.
doi_str_mv 10.1007/BF00357027
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80222879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80222879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c156t-2d455e5c9098d767e24200d0091b927dff65981b3fc6bdeea0bde1d3aaa1337e3</originalsourceid><addsrcrecordid>eNpFkE1LxDAURYMo4zi6cS905UKovrw0TbLU4qgw4EbXJW1encr0w6QV-u-tzKCbe-FyuIvD2CWHWw6g7h7WAEIqQHXEllwqEStM-DFbgkGIBUJ6ys5C-IQZNkYv2AJRSa3VkkHWNb31dqi_KdpS07mptU1dhqirItsOtfV-Ow3beYqcHz_COTup7C7QxaFX7H39-JY9x5vXp5fsfhOXXKZDjC6RkmRpwGinUkWYIIADMLwwqFxVpdJoXoiqTAtHZGFO7oS1lguhSKzY9f63993XSGHImzqUtNvZlrox5BoQUSszgzd7sPRdCJ6qvPd1Y_2Uc8h_9eT_emb46vA6Fg25P_TgQ_wAbspfAg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80222879</pqid></control><display><type>article</type><title>Comparative hemodynamics of antiarrhythmic drugs</title><source>Springer Online Journal Archives (Through 1996)</source><creator>Sami, M</creator><creatorcontrib>Sami, M</creatorcontrib><description>It is important to consider the hemodynamic effects of antiarrhythmic drugs, because the majority of patients who require these drugs already have compromised cardiac function. The presently available antiarrhythmic agents vary in their potential for producing negative inotropic effects on the myocardium; they vary, as well, as to the mechanisms by which these effects are produced. The drugs in each of the Vaughan-Williams' classes are discussed in terms of the extent to which they affect cardiac output and the mechanisms by which they may depress cardiac function. Practically all antiarrhythmic agents can decrease cardiac output when administered intravenously. However, when given orally to patients with congestive heart failure, amongst Class I agents, encainide and mexilitine appear to have a reasonably good safety record with respect to the worsening of congestive heart failure. Class III antiarrhythmics also appear to be well tolerated in patients with severe LV dysfunction.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/BF00357027</identifier><identifier>PMID: 2275887</identifier><language>eng</language><publisher>United States</publisher><subject>Administration, Oral ; Anti-Arrhythmia Agents - administration &amp; dosage ; Anti-Arrhythmia Agents - pharmacology ; Hemodynamics - drug effects ; Humans ; Injections, Intravenous</subject><ispartof>Cardiovascular drugs and therapy, 1990-06, Vol.4 Suppl 3 (S3), p.545-548</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c156t-2d455e5c9098d767e24200d0091b927dff65981b3fc6bdeea0bde1d3aaa1337e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2275887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sami, M</creatorcontrib><title>Comparative hemodynamics of antiarrhythmic drugs</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><description>It is important to consider the hemodynamic effects of antiarrhythmic drugs, because the majority of patients who require these drugs already have compromised cardiac function. The presently available antiarrhythmic agents vary in their potential for producing negative inotropic effects on the myocardium; they vary, as well, as to the mechanisms by which these effects are produced. The drugs in each of the Vaughan-Williams' classes are discussed in terms of the extent to which they affect cardiac output and the mechanisms by which they may depress cardiac function. Practically all antiarrhythmic agents can decrease cardiac output when administered intravenously. However, when given orally to patients with congestive heart failure, amongst Class I agents, encainide and mexilitine appear to have a reasonably good safety record with respect to the worsening of congestive heart failure. Class III antiarrhythmics also appear to be well tolerated in patients with severe LV dysfunction.</description><subject>Administration, Oral</subject><subject>Anti-Arrhythmia Agents - administration &amp; dosage</subject><subject>Anti-Arrhythmia Agents - pharmacology</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><recordid>eNpFkE1LxDAURYMo4zi6cS905UKovrw0TbLU4qgw4EbXJW1encr0w6QV-u-tzKCbe-FyuIvD2CWHWw6g7h7WAEIqQHXEllwqEStM-DFbgkGIBUJ6ys5C-IQZNkYv2AJRSa3VkkHWNb31dqi_KdpS07mptU1dhqirItsOtfV-Ow3beYqcHz_COTup7C7QxaFX7H39-JY9x5vXp5fsfhOXXKZDjC6RkmRpwGinUkWYIIADMLwwqFxVpdJoXoiqTAtHZGFO7oS1lguhSKzY9f63993XSGHImzqUtNvZlrox5BoQUSszgzd7sPRdCJ6qvPd1Y_2Uc8h_9eT_emb46vA6Fg25P_TgQ_wAbspfAg</recordid><startdate>199006</startdate><enddate>199006</enddate><creator>Sami, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199006</creationdate><title>Comparative hemodynamics of antiarrhythmic drugs</title><author>Sami, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c156t-2d455e5c9098d767e24200d0091b927dff65981b3fc6bdeea0bde1d3aaa1337e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Administration, Oral</topic><topic>Anti-Arrhythmia Agents - administration &amp; dosage</topic><topic>Anti-Arrhythmia Agents - pharmacology</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sami, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sami, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative hemodynamics of antiarrhythmic drugs</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>1990-06</date><risdate>1990</risdate><volume>4 Suppl 3</volume><issue>S3</issue><spage>545</spage><epage>548</epage><pages>545-548</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><abstract>It is important to consider the hemodynamic effects of antiarrhythmic drugs, because the majority of patients who require these drugs already have compromised cardiac function. The presently available antiarrhythmic agents vary in their potential for producing negative inotropic effects on the myocardium; they vary, as well, as to the mechanisms by which these effects are produced. The drugs in each of the Vaughan-Williams' classes are discussed in terms of the extent to which they affect cardiac output and the mechanisms by which they may depress cardiac function. Practically all antiarrhythmic agents can decrease cardiac output when administered intravenously. However, when given orally to patients with congestive heart failure, amongst Class I agents, encainide and mexilitine appear to have a reasonably good safety record with respect to the worsening of congestive heart failure. Class III antiarrhythmics also appear to be well tolerated in patients with severe LV dysfunction.</abstract><cop>United States</cop><pmid>2275887</pmid><doi>10.1007/BF00357027</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0920-3206
ispartof Cardiovascular drugs and therapy, 1990-06, Vol.4 Suppl 3 (S3), p.545-548
issn 0920-3206
1573-7241
language eng
recordid cdi_proquest_miscellaneous_80222879
source Springer Online Journal Archives (Through 1996)
subjects Administration, Oral
Anti-Arrhythmia Agents - administration & dosage
Anti-Arrhythmia Agents - pharmacology
Hemodynamics - drug effects
Humans
Injections, Intravenous
title Comparative hemodynamics of antiarrhythmic drugs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T10%3A54%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20hemodynamics%20of%20antiarrhythmic%20drugs&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=Sami,%20M&rft.date=1990-06&rft.volume=4%20Suppl%203&rft.issue=S3&rft.spage=545&rft.epage=548&rft.pages=545-548&rft.issn=0920-3206&rft.eissn=1573-7241&rft_id=info:doi/10.1007/BF00357027&rft_dat=%3Cproquest_cross%3E80222879%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c156t-2d455e5c9098d767e24200d0091b927dff65981b3fc6bdeea0bde1d3aaa1337e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=80222879&rft_id=info:pmid/2275887&rfr_iscdi=true